Novo Nordisk’s weight loss drug Wegovy showed promising results in a Phase 3 trial for people with nonalcoholic steatohepatitis (NASH), a fatty liver disease. 37% of patients on Wegovy experienced improvement in liver scarring, compared to 23% on placebo. Additionally, 63% of those on Wegovy achieved resolution of their symptoms with no worsening of fibrosis, compared to 34% on placebo. These results are seen as supporting regulatory approval for Wegovy as a treatment for NASH. The company believes that Wegovy could potentially provide a beneficial treatment option for people with this liver disease.
Source link
With new Wegovy data in hand, Novo Nordisk will file for approval in MASH
